Bank of America
PHAS

Bank of America’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Bank of America’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-193
Closed – – 8734
2022
Q3 		$0 Hold
193
– – ﹤0.01% 8490
2022
Q2 		$0 Buy
193
+192
+19,200% +$184 ﹤0.01% 8720
2022
Q1 		$0 Sell
1
-298
-100% -$483 ﹤0.01% 9061
2021
Q4 		$1K Sell
299
-5,197
-95% -$15.7K ﹤0.01% 8132
2021
Q3 		$17K Sell
5,496
-1,569
-22% -$5.24K ﹤0.01% 7447
2021
Q2 		$26K Sell
7,065
-15,105
-68% -$50.3K ﹤0.01% 7066
2021
Q1 		$77K Buy
22,170
+15,110
+214% +$61.3K ﹤0.01% 6494
2020
Q4 		$24K Buy
7,060
+1,393
+25% +$4.99K ﹤0.01% 6553
2020
Q3 		$20K Sell
5,667
-1,504
-21% -$6.06K ﹤0.01% 6289
2020
Q2 		$33K Buy
7,171
+3,038
+74% +$13.5K ﹤0.01% 6137
2020
Q1 		$14K Sell
4,133
-595
-13% -$2.72K ﹤0.01% 6275
2019
Q4 		$28K Sell
4,728
-746
-14% -$3.07K ﹤0.01% 6430
2019
Q3 		$22K Buy
5,474
+2,748
+101% +$21.9K ﹤0.01% 6569
2019
Q2 		$35K Sell
2,726
-1,124
-29% -$13.8K ﹤0.01% 6432
2019
Q1 		$37K Buy
+3,850
New +$15.2K ﹤0.01% 6309

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America's PHAS Position: Q4 2022 in Review

Bank of America sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 193 shares.

Bank of America first reported a position in PHAS in Q1 2019 and held it in 15 quarters. The position peaked at $77K in Q1 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Bank of America reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Bank of America sold 193 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Bank of America first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • Bank of America's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $77K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.